WAM
CLDI icon

Warberg Asset Management’s Calidi Biotherapeutics CLDI Stock Holding History

Warberg Asset Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$59.5K Buy
+250,000
New +$188K 0.01% 145
2025
Q4 		– Sell
-18,705
Closed -$28.4K – 190
2025
Q3 		$28.4K Buy
+18,705
New +$79.4K ﹤0.01% 160

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return

Warberg Asset Management's CLDI Position: Q1 2026 in Review

Warberg Asset Management opened a new position in Calidi Biotherapeutics (CLDI) in Q1 2026: 250,000 shares worth $59.5K. The stake represents 0.01% of the portfolio and ranks #145 among its holdings. This is a return to the name: Warberg Asset Management previously reported a position in CLDI as recently as Q3 2025.

Warberg Asset Management first reported a position in CLDI in Q3 2025 and has held it in 2 quarters since. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

  • Warberg Asset Management held 250,000 shares of Calidi Biotherapeutics worth $59.5K as of Q1 2026.
  • Calidi Biotherapeutics was a new Warberg Asset Management position in Q1 2026.
  • Calidi Biotherapeutics made up 0.01% of Warberg Asset Management's portfolio in Q1 2026, its #145 holding.
  • Warberg Asset Management first reported a position in Calidi Biotherapeutics in Q3 2025 and has held it in 2 quarters since.
  • 28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on Warberg Asset Management's 13F filing for Q1 2026, filed 7 May 2026.